Abridge stock $124.33 USD
Private-market facts for current and former Abridge employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Abridge uses AI to automatically generate structured clinical documentation from doctor-patient conversations, reducing physician burnout and improving medical record accuracy.
Abridge outlook
For employees evaluating Abridge equity, a 2x base multiple suggests limited near-term upside at current levels. The upside scenario at 3x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Abridge shares
Why shareholders consider selling
Shareholders in Abridge may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Abridge does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Abridge stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Abridge shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Abridge shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round, its reported $5B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Abridge shareholders
Exploring equity in Abridge often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Abridge most recently raised a Series C round in February 2024. The company was valued at $5B. Total funding raised to date is approximately $212M.
Lead investors in this round include Lightspeed Venture Partners and Venrock.
Founders & company background
Abridge was founded in 2018 by Shiv Rao, Sandeep Konam and is headquartered in Pittsburgh, PA.
Investors
Industry
Similar private companies
Latest Abridge news
Frequently asked questions
- Is Abridge still a private company?
- Yes, Abridge is currently a private company.
- What is Abridge's latest funding round?
- Abridge's most recent known round is Series C, raised in February 2024.
- What is Abridge's valuation?
- Abridge's latest reported valuation is $5B.
- Who are the investors in Abridge?
- Notable investors include Lightspeed Venture Partners, Venrock, Union Square Ventures, CVS Health Ventures, NVIDIA.
- Can I sell my Abridge stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Abridge stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Abridge data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.